Product Code: 978-1-68038-994-4
Computer Aided Detection Market Growth & Trends:
The global computer aided detection market size was estimated to reach USD 1,310.3 million by 2030 and is anticipated to expand at a CAGR of 5.9% during the forecast period, according to a study by Grand View Research, Inc.. CAD software tools have been introduced to support radiologists to cope with the growing number of images requiring interpretation. Increasing incidence rate of breast, prostate and lung cancer, rising technological advancements, and increasing use of CAD with other imaging modalities such as ultrasound and magnetic resonance imaging are expected to serve this industry as high-impact rendering drivers.
In the U.S., prostate cancer is one of the most common cancers amongst men and has increased the demand for multi-parametric Magnetic Resonance Imaging (MP-MRI) CADx systems for diagnosis and detection of prostate cancer.
In screening mammography, the traditional concept of double reading by the second clinician is expected to be replaced by CAD, of breast cancer completely. This is due to the additional reimbursement generated by computer-aided detection unlike the double readings that demand more of radiologists' time without any reimbursement for the second read.
Wide research has been undertaken to come up with new findings establishing the relation of cancer with anatomy. For instance, Johns Hopkins researchers established the presence of dense clumps of bacteria in ascending colon to cancer.
CAD is most widely used for breast cancer imaging due to a higher incidence of cancer in women with morbidity of 14 million new cases and 8.2 deaths according to the WHO 2012. With the increasing demand for imaging and the growing rate of chronic diseases, the demand for imaging technologies is expected to increase. Computer aided detection is now used with other imaging modalities such as ultrasound, nuclear imaging, magnetic resonance imaging, etc.
In 2014, mammography dominated the industry as the prevalence of cancer is high and is the leading cause of morbidity and mortality. According to the World Cancer Research Fund International 2012, North America and Oceania have the highest incidence rate of breast cancer and Asia and Africa has the lowest.
Digital imaging technique advancements are the other contributing factors for market growth as it has increased ease-of-integration of CAD solutions with imaging equipment and has also improved the efficiency of computer aided detection solutions.
Computer Aided Detection Market Report Highlights:
- In 2022, mammography dominated the market due to the fact that it has high potential for breast cancer imaging and was one of the first segments in which companies developed CAD software and till date most of it is working on this indication.
- According to the World Health Organization (WHO) estimates, in 2022, cancer is the leading cause of death worldwide, resulting in approximately 10 million deaths in 2020, or nearly one in six deaths.
- The demand for CAD has grown in chest imaging such as low-dose lung cancer screening due to Multidetector Computed Tomography (MDCT) indications. Furthermore, CAD has been brought in use for established areas of chest CT such as diagnosis of interstitial lung disease and acute Pulmonary Embolism (PE).
- CAD is also used with other imaging modalities such as x-ray, computed tomography, and ultrasound. Out of these, the use of CAD for x-ray imaging is the highest as it is the basic imaging and due to the recent advances overcoming its limitations of soft tissue imaging.
- North America was the most revenue generating region of the market. The market contributed more than 45.9% of the revenue in 2022. Constant efforts to fuel the market with newer technologies and the use of computer aided detection for integrative diagnosis apart from image analysis are expected to drive regional market growth over the forecast period.
- Asia Pacific is expected to grow at the fastest CAGR of 7.4% during the forecast period. The high prevalence of cancer-related mortality is a key factor driving the demand for computer-aided cancer detection and diagnosis.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Application
- 1.1.2. Indication
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. Indication outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Computer Aided Detection Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.3.3. Industry challenges
- 3.4. Computer Aided Detection Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Computer Aided Detection: Application Estimates & Trend Analysis
- 4.1. Computer Aided Detection Market: Key Takeaways
- 4.2. Computer Aided Detection Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Tuberculosis
- 4.3.1. Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
- 4.4. Breast Cancer
- 4.4.1. Breast cancer market estimates and forecast 2018 to 2030 (USD Million)
- 4.5. Lung Cancer
- 4.5.1. Lung cancer market estimates and forecast 2018 to 2030 (USD Million)
- 4.6. Colon/Rectal Cancer
- 4.6.1. Colon/Rectal cancer market estimates and forecast 2018 to 2030 (USD Million)
- 4.7. Prostate Cancer
- 4.7.1. Prostate cancer market estimates and forecast 2018 to 2030 (USD Million)
- 4.8. Liver Cancer
- 4.8.1. Liver cancer market estimates and forecast 2018 to 2030 (USD Million)
- 4.9. Bone Cancer
- 4.9.1. Bone cancer market estimates and forecast 2018 to 2030 (USD Million)
- 4.10. Cardiovascular/Neurological/Musculoskeletal Cancer
- 4.10.1. Cardiovascular/neurological/musculoskeletal indications market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Computer Aided Detection: Indication Estimates & Trend Analysis
- 5.1. Computer Aided Detection Market: Key Takeaways
- 5.2. Computer Aided Detection Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. X-ray Imaging
- 5.3.1. X-ray market estimates and forecast 2018 to 2030 (USD Million)
- 5.4. Magnetic Resonance Imaging
- 5.4.1. Magnetic resonance imaging market estimates and forecast 2018 to 2030 (USD Million)
- 5.5. Ultrasound Resonance Imaging
- 5.5.1. Ultrasound resonance imaging market estimates and forecast 2018 to 2030 (USD Million)
- 5.6. Nuclear Resonance Imaging
- 5.6.1. Nuclear resonance imaging market estimates and forecast 2018 to 2030 (USD Million)
- 5.7. Computed Tomography
- 5.7.1. Computed tomography market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Computer Aided Detection Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Computer Aided Detection Market by Region: Key Takeaways
- 6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Sweden
- 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Norway
- 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7. MEA
- 6.7.1. Saudi Arabia
- 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. EDDA Technology, Inc
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. FUJIFILM Holdings Corporation
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. Hologic, Inc
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Koninklijke Philips N.V
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. Siemens
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives NANO-X IMAGING LTD.
- 7.2.6. NANO-X IMAGING LTD.
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. CANON MEDICAL SYSTEMS CORPORATION
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. GENERAL ELECTRIC
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives
- 7.2.9. IBM
- 7.2.9.1. Company overview
- 7.2.9.2. Financial performance
- 7.2.9.3. Product benchmarking
- 7.2.9.4. Strategic initiatives
- 7.2.10. Riverain Technologies
- 7.2.10.1. Company overview
- 7.2.10.2. Financial performance
- 7.2.10.3. Product benchmarking
- 7.2.10.4. Strategic initiatives
- 7.2.11. iCAD Inc
- 7.2.11.1. Company overview
- 7.2.11.2. Financial performance
- 7.2.11.3. Product benchmarking
- 7.2.11.4. Strategic initiatives
- 7.2.12. Median Technologies
- 7.2.12.1. Company overview
- 7.2.12.2. Financial performance
- 7.2.12.3. Product benchmarking
- 7.2.12.4. Strategic initiatives
- 7.2.13. Hitachi Ltd
- 7.2.13.1. Company overview
- 7.2.13.2. Financial performance
- 7.2.13.3. Product benchmarking
- 7.2.13.4. Strategic initiatives
- 7.2.14. Shimadzu Analytical (India) Pvt. Ltd
- 7.2.14.1. Company overview
- 7.2.14.2. Financial performance
- 7.2.14.3. Product benchmarking
- 7.2.14.4. Strategic initiatives
- 7.2.15. Carestream Health
- 7.2.15.1. Company overview
- 7.2.15.2. Financial performance
- 7.2.15.3. Product benchmarking
- 7.2.15.4. Strategic initiatives
- 7.2.16. ESAOTE SPA
- 7.2.16.1. Company overview
- 7.2.16.2. Financial performance
- 7.2.16.3. Product benchmarking
- 7.2.16.4. Strategic initiatives
- 7.2.17. Narayana Hrudayalaya Ltd
- 7.2.17.1. Company overview
- 7.2.17.2. Financial performance
- 7.2.17.3. Product benchmarking
- 7.2.17.4. Strategic initiatives
- 7.2.18. Karyopharm
- 7.2.18.1. Company overview
- 7.2.18.2. Financial performance
- 7.2.18.3. Product benchmarking
- 7.2.18.4. Strategic initiatives